Overview Sepsis , insulin and noninvasive ventilation

The paper reports presented here reflect the current leading issues in the intensive care literature, the search for the ‘magic bullet’ in sepsis being an obvious example. Many of the trials in sepsis that are currently being reported were presented at recent conferences [1]. This is the case for the KyperSept Antithrombin III Study (see paper report) [2]. The summary of this paper highlights the disappointment of the study: “ATIII [antithrombin III] joins a long list of promising experimental agents for sepsis that failed to show a significant benefit in a multicentre, randomised phase III clinical trial.”